A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 8/67 (2006.01) A61K 8/34 (2006.01) A61K 31/05 (2006.01) A61K 31/375 (2006.01) A61K 31/665 (2006.01) A61K 33/04 (2006.01) A61K 45/06 (2006.01) A61P 17/00 (2006.01) A61Q 19/02 (2006.01)
Patent
CA 2450685
The present invention addresses the problem of excessive discoloration in hydroquinone compositions of a neutral pH. Antioxidants in the hydroquinone phase and inorganic or amino acyl cationic salts of acidic ascorbyl esters, preferably sodium metabisulfite and magnesium ascorbyl phosphate respectively, are effective in stabilizing such hydroquinone compositions, which are used in treatment of pigmentation disorders. Protected retinoid may be added to these compositions for additional skin benefit effects.
La présente invention concerne le problème d'une décoloration excessive de compositions d'hydroquinone à un pH neutre. Des antioxydants dans la phase hydroquinone et des sels inorganiques ou aminoacyle cationiques d'ascorbyle esters acides, de préférence du métabisulfite de sodium et de l'ascorbyle phosphate de magnésium respectivement, sont efficaces pour stabiliser lesdites compositions d'hydroquinone qui sont utilisées dans le traitement de troubles de la pigmentation. Un rétinoïde protégé peut être ajouté à ces compositions en vue d'obtenir pour la peau des effets bénéfiques supplémentaires.
Gans Eugene H.
Gordon Philip J.
Patel Bhiku G.
Wortzman Mitchell S.
Blake Cassels & Graydon Llp
Medicis Pharmaceutical Corp.
Taro Pharmaceuticals U.s.a. Inc.
LandOfFree
Compositions for the treatment of pigmentation disorders and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the treatment of pigmentation disorders and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the treatment of pigmentation disorders and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2025665